-
公开(公告)号：US20060135610A1
公开(公告)日：2006-06-22
申请号：US11021282
申请日：2004-12-22
IPC分类号： A61K31/202 , A61K31/225
CPC分类号： A61K45/06 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/525 , A61K2300/00
摘要： Compositions that promote and/or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and/or maintain cardiovascular health through the prevention, stabilization, reversal and/or treatment of coronary artery disease and/or cerebrovascular disease. Such compositions may be used independently to promote and/or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and/or a health deteriorating condition.
摘要翻译： 提供通过治疗一种或多种心血管疾病促进和/或维持心血管健康的组合物。 还提供了通过预防，稳定，逆转和/或治疗冠状动脉疾病和/或脑血管疾病来使用促进和/或维持心血管健康的组合物的方法。 这样的组合物可以独立地用于促进和/或维持心血管健康，或与用于治疗衰老和/或健康恶化状况共同的各种其它疾病状态的一种或多种其它组合物组合使用。
-
公开(公告)号：US20060134227A1
公开(公告)日：2006-06-22
申请号：US11020801
申请日：2004-12-22
IPC分类号： A61K33/26 , A61K31/19 , A61K31/375
CPC分类号： A61K31/375 , A61K9/0053 , A61K31/19 , A61K31/191 , A61K31/194 , A61K31/295 , A61K31/341 , A61K33/26 , A61K2300/00
摘要： Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention, stabilization, reversal and/or treatment of disorders associated with iron deficiency.
摘要翻译： 提供了通过用有机酸和任选类似的铁吸收促进剂施用铁来促进和/或维持膳食铁吸收的营养或膳食补充剂组合物。 还提供了使用一种或多种通过预防，稳定，逆转和/或治疗与铁缺乏相关的疾病来促进和/或维持健康的营养或膳食补充的方法。
-
公开(公告)号：US20130172279A1
公开(公告)日：2013-07-04
申请号：US13557527
申请日：2012-07-25
IPC分类号： A61K31/7056 , A61K9/00 , A61K31/4174
CPC分类号： A61K31/7056 , A61K9/0034 , A61K31/00 , A61K31/4174 , A61K31/56 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
摘要翻译： 药物组合物包含（a）抗菌有效量的抗菌剂，例如包括克林霉素或其药学上可接受的盐或酯; 和（b）抗真菌有效量的抗真菌剂，例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用，并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。
-
公开(公告)号：US20060140990A1
公开(公告)日：2006-06-29
申请号：US11326979
申请日：2006-01-05
申请人： Jonathan Bortz , R. Levinson , Mitchell Kirschner , Robert Cuca
发明人： Jonathan Bortz , R. Levinson , Mitchell Kirschner , Robert Cuca
IPC分类号： A61K31/7034 , A61K9/00
CPC分类号： A61K31/7056 , A61K9/0034 , A61K31/00 , A61K31/4174 , A61K31/56 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
摘要翻译： 药物组合物包含（a）抗菌活性量的抗菌剂，例如包括克林霉素或其药学上可接受的盐或酯，和（b）抗真菌有效量的抗真菌剂，例如包括布可康唑或其药学上可接受的盐或 的酯。 该组合物适用于以外阴阴道表面的单位剂量施用，并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。
-
公开(公告)号：US20110251141A1
公开(公告)日：2011-10-13
申请号：US13164326
申请日：2011-06-20
IPC分类号： A61K31/7056 , A61P31/00 , A61P31/04 , A61P15/02
CPC分类号： A61K31/7056 , A61K9/0034 , A61K31/00 , A61K31/4174 , A61K31/56 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
摘要翻译： 药物组合物包含（a）抗菌有效量的抗菌剂，例如包括克林霉素或其药学上可接受的盐或酯; 和（b）抗真菌有效量的抗真菌剂，例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用，并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。
-
公开(公告)号：US20070224226A1
公开(公告)日：2007-09-27
申请号：US11617180
申请日：2006-12-28
申请人： R. Levinson , Jonathan Bortz , Mitchell Kirschner , Robert Cuca
发明人： R. Levinson , Jonathan Bortz , Mitchell Kirschner , Robert Cuca
IPC分类号： A61K9/00 , A61K31/4172
CPC分类号： A61K9/0034 , A61K31/4164 , A61K31/4172 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises (a) metronidazole in an antibacterially effective amount; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
摘要翻译： 药物组合物包含（a）抗菌活性量的甲硝唑; 和（b）抗真菌有效量的抗真菌剂，例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用，并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。
-
公开(公告)号：US20120022162A1
公开(公告)日：2012-01-26
申请号：US13189893
申请日：2011-07-25
IPC分类号： A61K31/198 , A23L1/304 , A23L2/52 , A23L1/05 , C07F15/00 , C07F9/00 , C07F13/00 , C07F11/00 , C07F1/00 , C07F3/00 , A23L1/305 , C07C229/24
CPC分类号： A23L33/175 , A23L33/16 , A23L33/165 , A23V2002/00 , A23V2250/1592 , A23V2250/1628 , A23V2250/044 , A23V2250/061 , A23V2250/0622
摘要： Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.
摘要翻译： 混合的氨基酸/矿物化合物可包括与中心矿物原子结合的至少两个氨基酸。 可以调整氨基酸的组合以提供矿物质的改善的溶解度，吸收和/或生物利用度。 任选地，有机酸可以与矿物结合或与螯合物结合，以进一步改善溶解度，吸收和/或生物利用度。 包括一种或多种混合氨基酸/矿物化合物的组合物可以包括在用于矿物可以治疗和/或预防病症或症状的适应症的治疗方案中。
-
公开(公告)号：US20080139655A1
公开(公告)日：2008-06-12
申请号：US11850063
申请日：2007-09-05
IPC分类号： A61K31/195 , A61P25/28
CPC分类号： A61K31/198 , A61K9/0065 , A61K9/205 , A61K9/2054
摘要： A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.
摘要翻译： 提供包含左旋多巴的药物组合物，其以约6至约24小时的剂量间隔以约100至约500mg的单位剂量的左旋多巴施用时，显示足够长的释放期和足够长的停留时间 上消化道提供受试者血浆中左旋多巴的谷浓度，其不低于在受试者中观察到不良运动效应的最低阈值浓度。 还提供了治疗受试者中帕金森病的方法，其包括以约3至约24小时的剂量间隔以约50至约1000mg的单位剂量的左旋多巴口服施用该组合物。
-
公开(公告)号：US20070154516A1
公开(公告)日：2007-07-05
申请号：US11617199
申请日：2006-12-28
申请人： Jonathan Bortz , R. Levinson
发明人： Jonathan Bortz , R. Levinson
IPC分类号： A61K31/7048 , A61K31/7034 , A61K31/496 , A61K31/43 , A61K31/545
CPC分类号： A61K9/0034 , A61K9/06 , A61K31/00 , A61K31/43 , A61K31/496 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises a first active (e.g., antibacterial) agent and a second (e.g., antifungal) active agent, and comprises a component that is adapted for bioadhesion to a vulvovaginal surface. The composition provides differential release of the active agents at such a surface, wherein the second active agent exhibits a release profile that is substantially delayed, extended and/or inverted relative to the release profile of the first active agent.
摘要翻译： 药物组合物包含第一活性（例如抗细菌剂）和第二（例如抗真菌）活性剂，并且包含适于生物粘附到外阴阴道表面的组分。 组合物在这样的表面提供活性剂的差异释放，其中第二活性剂表现出相对于第一活性剂的释放曲线基本上延迟，延伸和/或翻转的释放特性。
-
公开(公告)号：US20070172551A1
公开(公告)日：2007-07-26
申请号：US11623476
申请日：2007-01-16
申请人： R. Thompson , Clayton Ericson , Stephen Ashmead , Jonathan Bortz
发明人： R. Thompson , Clayton Ericson , Stephen Ashmead , Jonathan Bortz
IPC分类号： A23L1/30
CPC分类号： A23L33/175 , A23L33/16 , A23L33/165 , A23V2002/00 , A23V2250/1592 , A23V2250/1628 , A23V2250/044 , A23V2250/061 , A23V2250/0622
摘要： Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.
摘要翻译： 混合的氨基酸/矿物化合物可包括与中心矿物原子结合的至少两个氨基酸。 可以调整氨基酸的组合以提供矿物质的改善的溶解度，吸收和/或生物利用度。 任选地，有机酸可以与矿物结合或与螯合物结合，以进一步改善溶解度，吸收和/或生物利用度。 包括一种或多种混合氨基酸/矿物化合物的组合物可以包括在用于矿物可以治疗和/或预防病症或症状的适应症的治疗方案中。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.026 秒)
